Veracyte Inc. (VCYT)

24.50
NASDAQ : Health Technology
Prev Close 24.57
Day Low/High 24.26 / 24.97
52 Wk Low/High 7.05 / 26.80
Avg Volume 730.70K
Exchange NASDAQ
Shares Outstanding 47.14M
Market Cap 1.16B
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Veracyte Names Sangeeta Bhorade, M.D., Medical Director Of Pulmonology

Veracyte Names Sangeeta Bhorade, M.D., Medical Director Of Pulmonology

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Sangeeta Bhorade, M.

Veracyte To Present At The UBS Global Healthcare Conference

Veracyte To Present At The UBS Global Healthcare Conference

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that Bonnie H.

Veracyte Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Veracyte Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 6,325,000 shares of common stock, including 825,000 shares sold upon full exercise of the underwriters' option to purchase additional shares, at a price to the public of...

Veracyte Announces Pricing Of Public Offering Of 5,500,000 Shares Of Common Stock

Veracyte Announces Pricing Of Public Offering Of 5,500,000 Shares Of Common Stock

Veracyte, Inc. (Nasdaq: VCYT) (the "Company") today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $23.

Veracyte Announces Proposed Public Offering Of Common Stock

Veracyte Announces Proposed Public Offering Of Common Stock

Veracyte, Inc. (Nasdaq: VCYT) ("the Company") today announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock.

Veracyte Announces First Quarter 2019 Financial Results

Veracyte Announces First Quarter 2019 Financial Results

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced financial results for the first quarter ended March 31, 2019 and provided an update on recent business progress.

Veracyte Receives Regulatory Authorization To Offer Envisia Genomic Classifier For Patients In New York State

Veracyte Receives Regulatory Authorization To Offer Envisia Genomic Classifier For Patients In New York State

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that it has received regulatory authorization from the New York State Department of Health to offer the Envisia™ Genomic Classifier for patients in the state effective...

Veracyte Names Alfred Bowie, Jr., Ph.D., As Vice President, Corporate And Business Development (Photo: Business Wire)

Veracyte Names Alfred Bowie, Jr., Ph.D., As Vice President, Corporate And Business Development (Photo: Business Wire)

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that it has named Alfred "Freddie" Bowie, Jr.

Veracyte Announces Publication Highlighting Afirma GSC's Ability To Rule Out Cancer In Challenging Thyroid Nodule Subtype

Veracyte Announces Publication Highlighting Afirma GSC's Ability To Rule Out Cancer In Challenging Thyroid Nodule Subtype

Veracyte, Inc. announced today that a new study published online in BMC Systems Biology showcases the development of the Afirma ® Genomic Sequencing Classifier (GSC) and its ability to distinguish benign from likely-cancerous Hürthle cells, a common, but...

Veracyte To Release First Quarter 2019 Financial Results On April 30, 2019

Veracyte To Release First Quarter 2019 Financial Results On April 30, 2019

Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the first quarter 2019 after the close of market on Tuesday, April 30, 2019.

Veracyte Announces Data Published In The Lancet Respiratory Medicine Demonstrate That The Envisia Genomic Classifier Improves Diagnosis Of IPF

Veracyte Announces Data Published In The Lancet Respiratory Medicine Demonstrate That The Envisia Genomic Classifier Improves Diagnosis Of IPF

Veracyte, Inc. announced that data published online today in The Lancet Respiratory Medicine suggest that use of the company's Envisia Genomic Classifier improves diagnosis for patients undergoing evaluation for interstitial lung diseases (ILDs),...

These Intriguing ETFs Are on the Cutting Edge of Disruptive Technologies

These Intriguing ETFs Are on the Cutting Edge of Disruptive Technologies

Ark Invest has developed a series of specialized exchange-traded funds that own shares in companies involved in 'disruptive innovation.'

Veracyte Announces Participation In The 18th Annual Needham Healthcare Conference

Veracyte Announces Participation In The 18th Annual Needham Healthcare Conference

Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced that Bonnie H.

Veracyte Announces New Afirma Xpression Atlas Data That Advance Genomic Understanding Of Medullary Thyroid Cancer

Veracyte Announces New Afirma Xpression Atlas Data That Advance Genomic Understanding Of Medullary Thyroid Cancer

Veracyte, Inc. (Nasdaq: VCYT) announced today that new data from the Afirma® Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC) are associated with variants from three genes.

Interesting VCYT Put And Call Options For May 17th

Interesting VCYT Put And Call Options For May 17th

Investors in Veracyte Inc saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VCYT options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

Veracyte Announces Sponsorship Of The Climb To Fight Cancer's Team Kilimanjaro Expedition

Veracyte Announces Sponsorship Of The Climb To Fight Cancer's Team Kilimanjaro Expedition

Veracyte, Inc. (Nasdaq: VCYT), a leading genomics diagnostics company, today announced its "Summit" level sponsorship of the Climb to Fight Cancer's Team Kilimanjaro expedition as part of the company's expanded efforts to combat this disease.

Veracyte Announces New Afirma Xpression Atlas Data On Medullary Thyroid Cancer To Be Presented At ENDO 2019

Veracyte Announces New Afirma Xpression Atlas Data On Medullary Thyroid Cancer To Be Presented At ENDO 2019

Veracyte, Inc. (Nasdaq: VCYT) announced today that new data derived from the Afirma® Xpression Atlas, which help characterize the genomic underpinning of medullary thyroid cancer (MTC), will be presented at ENDO 2019, the Endocrine Society's annual...

Veracyte Receives Final Medicare Coverage Policy For Envisia Genomic Classifier

Veracyte Receives Final Medicare Coverage Policy For Envisia Genomic Classifier

Veracyte, Inc. (Nasdaq: VCYT) announced today that it has received a final Medicare local coverage determination (LCD) for the Envisia™ Genomic Classifier.

Veracyte Announces Fourth Quarter And Full-Year 2018 Financial Results And Provides 2019 Financial Outlook

Veracyte Announces Fourth Quarter And Full-Year 2018 Financial Results And Provides 2019 Financial Outlook

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results and business progress for the quarter and full year ended December 31, 2018, and provided financial guidance for 2019.

Veracyte Announces Participation In Upcoming Investor Conferences

Veracyte Announces Participation In Upcoming Investor Conferences

Veracyte, Inc. (Nasdaq: VCYT) today announced that members of its management team will be participating in two upcoming investor conferences.

First Week Of VCYT September 20th Options Trading

First Week Of VCYT September 20th Options Trading

Investors in Veracyte Inc saw new options become available this week, for the September 20th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 227 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Veracyte To Release Fourth Quarter And Full-Year 2018 Financial Results February 25, 2019

Veracyte To Release Fourth Quarter And Full-Year 2018 Financial Results February 25, 2019

Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the fourth quarter and full-year 2018 after the close of market on Monday, February 25, 2019.

Veracyte To Present At The 21st Annual Needham Growth Conference

Veracyte To Present At The 21st Annual Needham Growth Conference

Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H.

Veracyte Announces Strategic Collaboration With Johnson & Johnson Innovation In Battle Against Lung Cancer

Veracyte Announces Strategic Collaboration With Johnson & Johnson Innovation In Battle Against Lung Cancer

Veracyte, Inc. ("Veracyte") (Nasdaq: VCYT) announced today that it has entered into a long-term strategic collaboration with Johnson & Johnson Innovation LLC * and the Lung Cancer Initiative at Johnson & Johnson to advance the development and...

Veracyte To Present At The 37th Annual J.P. Morgan Healthcare Conference

Veracyte To Present At The 37th Annual J.P. Morgan Healthcare Conference

Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H.

Veracyte Announces Expansion Of Envisia Genomic Classifier Early Access Program

Veracyte Announces Expansion Of Envisia Genomic Classifier Early Access Program

Veracyte, Inc. (Nasdaq: VCYT) today announced that 20 medical centers across the United States are now offering the Envisia Genomic Classifier through an Early Access Program (EAP) to patients who are undergoing evaluation for interstitial lung diseases...

Veracyte To Present At The Canaccord Genuity Medical Technologies & Diagnostics Forum

Veracyte To Present At The Canaccord Genuity Medical Technologies & Diagnostics Forum

Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H.

Veracyte Announces Publication Of Data Demonstrating "Real World" Performance Of Afirma GSC In Thyroid Cancer Diagnosis

Veracyte Announces Publication Of Data Demonstrating "Real World" Performance Of Afirma GSC In Thyroid Cancer Diagnosis

Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of "real world" data showing that the Afirma® Genomic Sequencing Classifier (GSC) enables even more patients to avoid unnecessary surgery in thyroid cancer diagnosis compared to the company's...

TheStreet Quant Rating: D (Sell)